Welcome to our dedicated page for Eli Lilly and news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly and stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. A conference call with investors, media and the public will begin at 10:00 a.m. Eastern that day and will be webcast live.
According to the company, a replay of the webcast will be posted on the investor website at https://investor.lilly.com/webcasts-and-presentations following the call.
Eli Lilly (NYSE:LLY) reported topline Phase 3 ACHIEVE-4 results for Foundayo (orforglipron) on April 16, 2026. Foundayo met the primary non-inferiority MACE-4 endpoint (HR 0.84; 95% CI 0.59–1.20) and showed superior A1C and weight reductions at 52 weeks vs insulin glargine. A pre-planned analysis reported 57% lower all-cause death (HR 0.43; 95% CI 0.25–0.75). Lilly plans an FDA submission for type 2 diabetes by end of Q2 2026.
Lilly (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-322 trial showing that adding Jaypirca (pirtobrutinib) to venetoclax plus rituximab produced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in relapsed/refractory CLL/SLL.
Results were consistent across subgroups, including patients previously treated with covalent BTK inhibitors. Overall survival was immature but trended favorably. Safety was consistent with known profiles and discontinuation rates were low and similar between arms. Lilly plans regulatory submissions later in 2026.
Eli Lilly (NYSE: LLY) announced Foundayo (orforglipron) is now available in the U.S. after FDA approval on April 1, 2026, with retail pharmacy shipping beginning April 9, 2026.
Foundayo is a once-daily oral GLP-1 for adults with obesity or overweight with weight-related problems, showing an average weight loss of 27.3 pounds (12.4%) at the highest dose in ATTAIN-1.
Eli Lilly (NYSE:LLY) announced FDA approval of Foundayo™ (orforglipron) for adults with obesity or overweight with weight-related conditions, available by prescription immediately and shipping from April 6, 2026. In ATTAIN-1, the highest dose produced an average 27.3 lb (12.4%) weight loss versus 2.2 lb (0.9%) placebo; overall trial participants lost 25 lb (11.1%) versus 5.3 lb (2.1%) placebo.
Foundayo will be distributed via LillyDirect with commercial copays from $25/month and self-pay starting at $149/month; Medicare Part D access may begin July 1, 2026. Safety warnings include potential thyroid tumors and common GI side effects.
Eli Lilly (NYSE: LLY) agreed to acquire Centessa Pharmaceuticals for $38.00 cash per share plus one CVR, yielding up to $47.00 per share if regulatory milestones are met. The upfront consideration implies an aggregate equity value of ~$6.3 billion and the CVR adds potential ~$1.5 billion.
The deal expands Lilly's neuroscience footprint into sleep medicine by adding Centessa's OX2R agonist portfolio, including lead candidate cleminorexton (Phase 2a) targeting narcolepsy and idiopathic hypersomnia. Closing is expected in Q3 2026, subject to shareholder, High Court and regulatory approvals.
Eli Lilly (NYSE: LLY) reported Phase 3b TOGETHER-PsA results showing that concomitant Taltz (ixekizumab) plus Zepbound (tirzepatide) was superior to Taltz alone at Week 36 across the primary endpoint and all key secondaries.
The combination delivered ACR50 plus ≥10% weight reduction in 31.7% versus 0.8%, higher ACR50 (33.5% vs 20.4%), greater ≥10% weight loss (84.5% vs 4.5%) and improved MDA, hsCRP, HAQ-DI, FACIT-Fatigue and SF-36 MCS.
Lilly (NYSE: LLY) reported interim ADlong Phase 3b data on March 27, 2026 showing long-term durability for EBGLYSS (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis. Observed results up to four years: EASI-75 94%, EASI-90 75%, IGA 0/1 68%, Pruritus NRS ≤4 78%.
Most patients (77%) received monotherapy, 80% achieved outcomes without topical corticosteroids, and monthly maintenance dosing produced sustained control; safety in year one was consistent with known profile.
Eli Lilly (NYSE: LLY) reported positive topline Phase 3 results for retatrutide in TRANSCEND-T2D-1 on March 19, 2026. At 40 weeks, retatrutide produced up to 2.0% A1C reduction and up to 16.8% weight loss (36.6 lbs) versus placebo, meeting primary and all key secondary endpoints.
Improvements were seen across doses (4 mg, 9 mg, 12 mg) and cardiovascular risk markers; common adverse events were nausea, diarrhea and vomiting, mostly during dose escalation.
Lilly (NYSE: LLY) reported positive topline Phase 3 ADorable-1 results for EBGLYSS (lebrikizumab-lbkz) in patients aged six months to 18 years with moderate-to-severe atopic dermatitis on March 16, 2026. At Week 16, EBGLYSS achieved EASI-75 63%, IGA 0,1 44%, EASI-90 39% and Pruritus NRS ≥4 improvement 35%. Safety was consistent with adult/adolescent studies, with no new signals and no injection site pain reported. Lilly plans regulatory submissions for potential pediatric label updates; the ADorable program and a 52-week extension continue.